Anti-aging composition, application thereof and skin care product

Abstract

The invention belongs to the technical field of cosmetics, and discloses an anti-aging composition and application thereof and a skin care product, the anti-aging composition comprises royal jelly polypeptide, a dendrobium officinale stem extract solution, a ginsenoside solution and copper gluconate; the mass ratio of the royal jelly polypeptide to the dendrobium officinale stem extract solution to the ginsenoside solution to the copper gluconate is (3-5): (18-22): (18-22): (4-6), and through cooperation of the royal jelly polypeptide, the dendrobium officinale stem extract solution, the ginsenoside solution and the copper gluconate, on one hand, the expression quantity of collagen is remarkably improved; on the other hand, the synergistic matching of the raw materials can also reduce the generation of MDA of oxidative damage cells so as to provide good oxidation resistance.

Description

Technical Field

[0001] This application belongs to the field of cosmetic technology and discloses an anti-aging composition and its uses, as well as skin care products. Background Technology

[0002] The skin, covering the surface of the human body and in direct contact with the external environment, is an organ that plays a role in protection, excretion, temperature regulation, and sensing external stimuli. It is the largest organ in the human body, and skin health is very important to the body. With age and the influence of the external environment, the metabolism of human skin slows down, the moisturizing factors in the dermis decrease, and the function of elastic fibers and collagen fibers in the dermis declines. The skin gradually shows signs of aging and exacerbates age-related damage, reducing the skin's ability to protect itself and regulate its functions. As a result, the skin cannot adapt to changes in the internal and external environment, and its tension and elasticity weaken, leading to wrinkles, dullness, and other signs of aging.

[0003] The desire for beauty is universal, and the need to delay skin aging and improve wrinkles, sagging, and other signs of aging is becoming increasingly urgent. Currently, anti-aging skincare products on the market primarily work through antioxidants, promoting collagen production, and moisturizing and repairing. Antioxidants such as Vitamin C, Vitamin E, and niacinamide can effectively eliminate free radicals and delay oxidative damage to the skin, but these ingredients are relatively unstable and easily deactivated by environmental factors such as light and air. Furthermore, the effect of a single antioxidant is limited in the face of long-term accumulated oxidative stress damage. Peptides can stimulate fibroblasts to synthesize collagen, but their penetration efficiency is low, and most only act on the skin surface, failing to penetrate deep into the dermis to address collagen loss at the cellular level. While moisturizing and repairing ingredients such as hyaluronic acid and ceramides can temporarily improve dry and rough skin, they cannot fundamentally inhibit collagen degradation caused by increased matrix metalloproteinase (MMP) activity, making it difficult to effectively intervene in the skin aging process. Furthermore, some anti-aging skincare products can easily irritate the skin, potentially causing irreversible damage, and their effects are limited.

[0004] Therefore, the problem to be solved by this application is to provide a safe and effective anti-aging composition. Summary of the Invention

[0005] The purpose of this application is to provide an anti-aging composition comprising royal jelly polypeptide, Dendrobium officinale stem extract solution, ginsenoside solution and copper gluconate. The combination of the above components has a significant synergistic effect and can exert a highly effective anti-aging effect.

[0006] In addition, this application also provides the use of an anti-aging composition and a skin care product.

[0007] To achieve the above objectives, this application provides the following technical solution: An anti-aging composition comprising royal jelly polypeptide, Dendrobium officinale stem extract solution, ginsenoside solution, and copper gluconate; wherein the mass ratio of the royal jelly polypeptide, Dendrobium officinale stem extract solution, ginsenoside solution, and copper gluconate is 3-5:18-22:18-22:4-6.

[0008] Preferably, it further includes a synergist, said synergist being selected from at least one of Inonotus obliquus extract and Fucus vesiculosus extract; The mass ratio of the synergist to royal jelly polypeptide, Dendrobium officinale stem extract solution, ginsenoside solution and copper gluconate is 4-6:3-5:18-22:18-22:4-6.

[0009] Preferably, the royal jelly polypeptide is a mixture of hydrolyzed royal jelly protein and maltodextrin, and the mass ratio of hydrolyzed royal jelly protein to maltodextrin is 1:8-10.

[0010] Preferably, the product comprises the following components by mass parts: Royal jelly polypeptides, 3-5 parts; 18–22 parts of Dendrobium officinale stem extract solution; 18-22 parts of ginsenoside solution; 4-6 parts of copper gluconate; 40-50 parts water; Butanediol 4-6 parts; 0.1 to 1 part of 1,2-hexanediol; 0.1 to 1 part of p-hydroxyacetophenone.

[0011] In addition, this application also discloses the use of the above-mentioned anti-aging composition in the preparation of skin care products.

[0012] In addition, this application also discloses a skin care product containing the above-mentioned anti-aging composition.

[0013] Preferably, the content of the anti-aging composition in the skin care product is 0.05wt% to 10wt%.

[0014] Preferably, the skin care product is one of the following: lotion, cream, spray, serum, essential oil, mask, and gel.

[0015] Compared with the prior art, the beneficial effects of this application are: This application utilizes the combination of royal jelly peptides, Dendrobium officinale stem extract solution, ginsenoside solution, and copper gluconate to significantly enhance collagen expression, thereby increasing elastin content. Furthermore, the synergistic combination of these ingredients reduces the generation of MDA in oxidatively damaged cells, thus providing excellent antioxidant capacity. Attached Figure Description

[0016] Figure 1 This is a schematic diagram showing the test results of the relative expression level of type III collagen gene. Figure 2 This is a schematic diagram of the elastin content test results; Figure 3 This is a schematic diagram of the test results for the upregulation rate of elastin content. Detailed Implementation

[0017] The technical solution of this application will be clearly and completely described below with reference to the embodiments thereof. Obviously, the described embodiments are only some embodiments of this application, and not all embodiments. Based on the embodiments of this application, all other embodiments obtained by those of ordinary skill in the art without creative effort are within the scope of protection of this application.

[0018] Product Information: Royal jelly polypeptide: purchased from Guangzhou Jikemeichuang Life Science Co., Ltd.; Dendrobium officinale stem extract solution: purchased from Guangzhou Jikemeichuang Life Science Co., Ltd.; Ginsenoside solution: purchased from Guangzhou Jikemeichuang Life Science Co., Ltd.; Copper gluconate: purchased from Zhengzhou Ruipu Bioengineering Co., Ltd.; Inonotus obliquus extract: purchased from Guangzhou Rancui Chemical Co., Ltd.; Fucus vesiculosus extract: purchased from Guangzhou Jiaye Biotechnology Co., Ltd.

[0019] The preparation method of the anti-aging composition is as follows: The solution was obtained by mixing royal jelly polypeptide, copper gluconate, p-hydroxyacetophenone, 1,2-hexanediol, ginsenoside solution, and Dendrobium officinale stem extract solution with pure water at room temperature and then filtering.

[0020] (It should be noted that, unless otherwise specified, the compositions in the following examples and comparative examples were all prepared using this method.) Examples 1-3 An anti-aging composition, the formulation of which is shown in Table 1; Table 1: Formulation table of anti-aging compositions in Examples 1-3 (parts by weight) Components Example 1 Example 2 Example 3 Royal jelly peptides 4 3 5 Dendrobium officinale stem extract solution 20 22 18 Ginsenoside solution 20 18 22 Copper gluconate 5 6 4 water 45 40 50 Butylene glycol 5 6 4 1,2-Hexanediol 0.5 1 0.1 p-Hydroxyacetophenone 0.5 1 0.1 Example 4

[0021] It is basically the same as Example 1, except that hydrolyzed royal jelly protein is used instead of royal jelly peptides.

[0022] Example 5

[0023] It is basically the same as Example 1, except that maltodextrin is used instead of royal jelly peptides.

[0024] Examples 6-8 An anti-aging composition, the formulation of which is shown in Table 2; Table 2: Formulation table of anti-aging compositions in Examples 6-8 (parts by weight) Components Example 6 Example 7 Example 8 Royal jelly peptides 4 4 4 Dendrobium officinale stem extract solution 20 20 20 Ginsenoside solution 20 20 20 Copper gluconate 5 5 5 Inonotus obliquus extract 5 0 2.5 Fucus vesiculosus extract 0 5 2.5 water 45 45 45 Butylene glycol 5 5 5 1,2-Hexanediol 0.5 0.5 0.5 p-Hydroxyacetophenone 0.5 0.5 0.5 Comparative Examples 1-12 A composition, the formulation of which is shown in Table 3: Table 3: Formulation table (parts by weight) for Comparative Examples 1-12 Components Royal jelly peptides Dendrobium officinale stem extract solution Ginsenoside solution Copper gluconate Zinc gluconate Chlorophyll copper water Butylene glycol 1,2-Hexanediol p-Hydroxyacetophenone Comparative Example 1 0 22 22 5 0 0 45 5 0.5 0.5 Comparative Example 2 8 0 36 5 0 0 45 5 0.5 0.5 Comparative Example 3 8 36 0 5 0 0 45 5 0.5 0.5 Comparative Example 4 0 22 22 0 5 0 45 5 0.5 0.5 Comparative Example 5 8 0 36 0 5 0 45 5 0.5 0.5 Comparative Example 6 8 36 0 0 5 0 45 5 0.5 0.5 Comparative Example 7 4 20 20 0 5 0 45 5 0.5 0.5 Comparative Example 8 0 22 22 0 0 5 45 5 0.5 0.5 Comparative Example 9 8 0 36 0 0 5 45 5 0.5 0.5 Comparative Example 10 8 36 0 0 0 5 45 5 0.5 0.5 Comparative Example 11 4 20 20 0 0 5 45 5 0.5 0.5 Performance testing: 1. Relative expression level of malondialdehyde (MDA) in cells 1.1 Malondialdehyde (MDA) is a lipid peroxidation end product formed after cellular peroxidation. MDA content is an important parameter reflecting the body's antioxidant potential, indicating the rate and intensity of lipid peroxidation and indirectly reflecting the degree of tissue oxidative damage. Accumulation of MDA leads to the cross-linking and precipitation of biomolecules such as proteins and nucleic acids, forming insoluble lipofuscin, thus accelerating aging. MDA level detection based on oxidative stress-induced cell damage models can explore the ability of test substances to combat oxidative stress and thus evaluate their anti-aging effects.

[0025] 1.2 Materials and Equipment 1.2.1 Cells: HaCaT cells (ATCCCRL-2404, human immortalized keratinocytes, US Standard Biological Collection Center) 1.2.2 Reagents: Vitamin C (ascorbic acid, purity ≥98%, source leaf), MDA detection kit (Nanjing Jiancheng, A003-4-1) 1.2.3 Equipment: CO2 incubator (Thermo, 150I), laminar flow hood (Sujing Antai, SW-CJ-1F), Olympus microscope (CK53), multi-functional microplate reader (TECAN, SPARK) 1.3 Sample processing The test sample was diluted with culture medium to a concentration of 2wt%, filtered through a 0.22μm microporous membrane, and the filtrate was collected as the mother liquor.

[0026] 1.4 Experimental Methods 1.4.1 Cell viability assay HaCaT cells were digested, resuspended, and seeded into 96-well plates. After 24 hours, the culture medium was discarded, and complete culture medium containing 2 wt% of the test sample was added (the composition prepared in the examples and comparative examples was used as the test sample). After 24 hours, OD570nm and OD630nm were detected by MTT assay to analyze the effect of the test sample on the growth of HaCaT cells.

[0027] 1.4.2 Relative expression level of MDA in cells HaCaT cells were digested, resuspended, and seeded into multiple 6-well plates. After 24 hours of cell adhesion, the culture medium containing 2 wt% of the compositions prepared in different examples and comparative examples was used as the test sample. The positive control group (PC) was pre-protected with culture medium containing 10 μg / mL ascorbic acid for 24 hours, while the blank control group (Control) was only treated with culture medium. After the treatment time, the old culture medium was discarded, and a small amount of PBS was added to each well for UVB irradiation at a dose of 48 mJ / cm². After irradiation, the PBS in the culture plate was discarded, and each group was cultured in the corresponding prepared culture medium for another 24 hours. Cells were collected, and the MDA content of the cells was calculated according to the instructions of the lipid oxidation (MDA) detection kit, as shown in Formula 1. Formula 1 C standard: Standard concentration, 10 nmol / mL; Cpr: Sample protein concentration, mg / mL (prot refers to protein), determined using the BCA method.

[0028] The test results are shown in Table 4: Group MDA relative expression level Group MDA relative expression level Example 1 -24% Comparative Example 4 -11% Example 2 -22% Comparative Example 5 -7% Example 3 -21% Comparative Example 6 -11% Example 4 -20% Comparative Example 7 -13% Example 5 -18% Comparative Example 8 -8% Example 6 -27% Comparative Example 9 -7% Example 7 -25% Comparative Example 10 -10% Example 8 -32% Comparative Example 11 -9% Comparative Example 1 -10% Blank group / Comparative Example 2 -8% Positive control -36% Comparative Example 3 -10% Table 4: Results of relative expression levels of malondialdehyde (MDA) in cells Results Analysis 1. As can be seen from Examples 1-3, when the amount of raw materials added to the composition is adjusted slightly, the antioxidant capacity of Examples 1-3 fluctuates, but the fluctuation range is relatively small. Further observation of Example 4 shows that when hydrolyzed royal jelly protein was used to replace royal jelly peptides, the relative expression level of MDA in the composition prepared in Example 4 increased by 4% compared with Example 1. This indicates that maltodextrin plays a certain role in antioxidant capacity in this case. Further observation of Example 5 shows that when maltodextrin was used to replace royal jelly peptides, the antioxidant capacity of the composition further declined. This indicates that the antioxidant performance of royal jelly peptides in this case comes from both hydrolyzed royal jelly protein and maltodextrin, which are its constituent raw materials. More importantly, when hydrolyzed royal jelly protein or maltodextrin is used alone, the antioxidant capacity of Examples 4-5 is not as good as that of Example 1. This indicates that there may be a synergistic effect between hydrolyzed royal jelly protein and maltodextrin to enhance the antioxidant capacity of the composition. 2. As can be seen from Examples 1 and 6-7, after adding Inonotus obliquus extract or Fucus vesiculosus extract to Example 1, the relative expression level of MDA in Examples 6-7 was further inhibited, indicating that the antioxidant capacity of the composition was further enhanced. Further observation of Example 8 shows that when Inonotus obliquus extract and Fucus vesiculosus extract were added to the composition at the same time, the MDA inhibition capacity of Example 8 was significantly better than that of either Example 6-7. Therefore, it can be seen that there may be a synergistic effect between Inonotus obliquus extract and Fucus vesiculosus extract to further enhance the antioxidant capacity of the composition. 3. As can be seen from Example 1 and Comparative Examples 1-3, when any one of the royal jelly peptides, Dendrobium officinale stem extract solution, and ginsenoside solution is missing from the composition, the antioxidant capacity of Comparative Examples 1-3 is significantly reduced compared to Example 1. This suggests that there may be a synergistic effect among royal jelly peptides, Dendrobium officinale stem extract solution, and ginsenoside solution to increase the antioxidant capacity of the composition. Further observation of Comparative Examples 4-7 reveals that Comparative Example 4-6 differs from Comparative Examples 1-3 only in that copper gluconate is replaced with zinc gluconate. Furthermore, Comparative Example 4-6 shows that its antioxidant capacity is quite similar to that of Comparative Examples 1-3, and in some cases it is even superior to that of Comparative Examples 1-3. Therefore, it is evident that the antioxidant capacity of zinc gluconate may be slightly better than that of copper gluconate. However, further observation of Comparative Example 7 shows that, given the known synergistic effect among royal jelly polypeptide, Dendrobium officinale stem extract solution, and ginsenoside solution, the improvement trend of Comparative Example 7 compared to Comparative Examples 4-6 is not obvious. In contrast, Example 1 showed a significant improvement in antioxidant capacity compared to Comparative Examples 1-3. This indicates that when royal jelly peptides, Dendrobium officinale stem extract solution, and ginsenoside solution coexist, they have a synergistic effect. Furthermore, when copper gluconate is used with all three, this synergistic effect may be further amplified, while zinc gluconate, which is also a gluconate, cannot achieve the same effect. Further experiments were conducted using copper chlorophyllin. When copper chlorophyllin was used to replace copper gluconate in Comparative Example 8-10 compared to Comparative Example 1-3, the antioxidant capacity of Comparative Example 8-10 was slightly inferior to that of Comparative Example 1-3. This suggests that the antioxidant capacity of copper chlorophyllin may be slightly weaker than that of copper gluconate. Further observation of Comparative Example 11 revealed that, given the known synergistic effect among royal jelly peptides, Dendrobium officinale stem extract solution, and ginsenoside solution, Comparative Example 11 showed almost no significant improvement compared to Comparative Examples 8-10. This indicates that when copper salt is used to replace copper gluconate, the copper salt cannot directly amplify the synergistic effect among royal jelly peptides, Dendrobium officinale stem extract solution, and ginsenoside solution.

[0029] 2. Relative expression level of type III collagen gene (qPCR) 2.1 Experimental Principle Ultraviolet (UV) radiation can lead to a continuous increase in the expression and activity of matrix metalloproteinases (MMPs) in the skin, degrading elastin and collagen in the skin's extracellular matrix and accelerating the skin aging process. Type III collagen is a major structural protein in the dermis. Synthesized in fibroblasts, its structure consists of fine reticular fibers, which together with type I collagen (thick bundles) form the skin's support network. Normal skin is mainly composed of type I and type III collagen, and its function is closely related to skin elasticity and repair ability.

[0030] 2.2 Equipment and Materials 2.2.1 Equipment: Multifunctional microplate reader (TECAN, SPARK), CO2 incubator (Thermo), Real-time PCR instrument (Bio-Rayet, CFXConnect Ooticsodule), PCR amplification instrument (Langji, A300) 2.2.2 Cell line: HDF (human dermal fibroblasts, Cybio (Shanghai) Biotechnology Co., Ltd.) 2.2.3 Reagents: Transforming growth factor β1 protein (Sigma), RNA rapid extraction kit (Meiji Biotechnology), qPCR Mix kit (SYBR Green) 2.3 Experimental Methods 2.3.1 Cell viability assay HDF cells were plated in 96-well plates. After 24 hours, the culture medium was aspirated, and complete culture medium containing different concentrations of the test sample (the composition prepared in Example 1) was added. After 24 hours, the OD570nm and OD630nm were detected by MTT assay, and the effect of the test sample on HDF cell growth was analyzed by t-test to screen suitable concentrations for efficacy testing.

[0031] 2.3.2 Cellular Type III Collagen Expression Assay Cells were diluted with cell culture medium to the seeding density (55%–65% confluence reached 24 h post-seeding) and seeded into 24-well plates, with 500 μL per well. After seeding, the plates were incubated in a CO2 incubator for 24 h ± 2 h. The culture medium in the 24-well plates was discarded, and 100 μL of PBS was added to each well to cover the cells. The plates were then irradiated with UVB at 48 mJ / cm². The blank control group was covered with aluminum foil to prevent cell exposure. After UVB irradiation, the cells were washed once with PBS, and the drug administration was carried out according to the experimental design in Table 5. The sample groups were added to culture medium containing the test substance, the positive control group was added to culture medium containing the positive control, and the blank / solvent control wells were added to cell culture medium and cultured for another 48 h.

[0032] Table 5: Experimental design of UVA-fibroblast model (qPCR)

[0033] After cell culture, total mRNA was extracted, quantified, and cDNA was obtained by reverse transcription for Real-Time PCR. The relative expression level of Collagentype III genes was analyzed using the 2-ΔΔCT method. The average Ct value of three replicates for each gene in each cDNA sample was used as the amplification result. The amplification level of GAPDH gene was used as the internal reference gene. The gene cycle threshold ΔCt was calculated as Ct = gene - CtGAPDH, and the relative gene expression level ΔΔCt = ΔCt test substance - ΔCt blank control. The ratio of expression levels between the test substance group and the control group was calculated using 2-ΔΔCT analysis.

[0034] Results Analysis: The test results are as follows: Figure 1 As shown, the expression level of Collagentype III gene in skin fibroblasts was significantly decreased after UVB irradiation oxidative damage (p<0.01). In the positive control group (PC), treatment with 100 ng / mTGF-β1 significantly upregulated Collagentype III gene expression compared to the model control group (NC) (p<0.01), demonstrating the effectiveness of the experimental system.

[0035] Treatment with 0.20% of the sample prepared in Example 1 (Sanmutong) significantly increased the expression of the collagen type III gene in cells compared with the model control group (NC). The results indicate that Sanmutong has an inhibitory effect on the decrease in type III collagen gene expression in human skin fibroblasts damaged by UVB irradiation.

[0036] 3. Elastin content assay (ELISA) 3.1 Experimental Principle Ultraviolet (UV) radiation can lead to a continuous increase in the expression and activity of matrix metalloproteinases (MMPs) in the skin, degrading elastin and collagen in the extracellular matrix of skin cells and accelerating the skin aging process. By constructing an oxidative damage model using UVA irradiation of human fibroblasts and measuring changes in elastin content after treatment with test substances, the ability of test substances to combat photoaging can be evaluated.

[0037] 3.2 Equipment and Materials 3.2.1 Equipment: CO2 incubator (Thermo, 150I), laminar flow hood (Sujing Antai, SW-CJ-1F), Olympus microscope (CK53), multi-functional microplate reader (TECAN, SPARK). 3.2.2 Cell line: HSF (human skin fibroblasts, Shanghai Boson Biotechnology Co., Ltd.); 3.2.3 Reagents: TGF-β1 was purchased from PEPROTECH, and the Human Elastinelisa assay kit was purchased from Huamei Biotechnology Co., Ltd. 3.3 Sample Preparation The test substance was filtered through a 0.22 μm filter membrane and diluted to the required concentration with cell culture medium.

[0038] 3.4 Experimental Methods 3.4.1 Cell Preparation Cells were cultured at 37°C and 5% CO2, with a cell density controlled at 1.0 × 10⁶ cells per mL. 4 ~5.0×10 5 Individual samples were passaged and used for biological activity assays 24–36 hours later.

[0039] 3.4.2 HSF cell viability test HaCaT cells in good growth condition were seeded into 96-well plates and cultured for 24 h. The medium was then replaced with a medium containing different concentrations of the test samples. After 24 h, the OD450nm value was measured by CCK-8 assay to analyze the effect of the test samples on the tolerance of HSF cells.

[0040] 3.4.3 Efficacy Testing Dilute cells to the seeding density using cell culture medium (confluence reaches 45%–60% after 24 hours) and seed into 24-well plates, 500 μL per well. After seeding, incubate in a CO2 incubator for 24 hours ± 2 hours. Discard the culture medium in the 24-well plates and perform drug administration according to the experimental design in Table 6. Add culture medium containing the test substance (the composition prepared in Example 1 (Sanmutong)) to the test wells, add culture medium containing the positive control to the positive control wells, and add cell culture medium to the blank / solvent control wells, 500 μL per well, for pre-protection drug administration for 24 hours. Remove the culture medium, add 100 μL of PBS to each well to cover the cells, and use 10 J / cm² water.2 The cells were irradiated with UVA, while the blank control group was covered with aluminum foil to prevent cell exposure. After UVA irradiation, the cells were washed once with PBS, and then cultured for another 48 hours with the prepared solutions for each group. Table 6: Experimental Design of UVA-Fibroblast Model (ELISA)

[0041] After incubation, the cell culture supernatant was collected into sterile centrifuge tubes and stored at -80°C. Elastin was detected according to the instructions for use of the human elastase-linked immunosorbent assay kit.

[0042] 5 Result Calculation The regression equation for the standard curve was calculated using the concentration and OD450 value of the standard. The OD450 value of the sample was then substituted into the equation to calculate the elastin content of the sample. The average value of the three replicates for each group was taken as the final elastin result. The elastin upregulation rate was calculated according to Equation 2.

[0043] Formula 2 In the formula, T represents the average elastin content of the test substance; C represents the average elastin content in the blank / negative control group.

[0044] The experimental results are shown in Table 7: Table 7: Results of Elastin Detection

[0045] Results analysis: The test results are shown in Table 7. Figure 2-3 As shown, elastin in skin fibroblasts degraded and its content decreased significantly after UVA irradiation and oxidative damage. In the positive control group (PC), treatment with 100 ng / mL LTGF-β1 significantly increased elastin content compared to the model control group (NC) (p<0.01), demonstrating the effectiveness of the experimental system.

[0046] After treatment with 0.1% and 0.2% of sulphurine, the elastin content of skin fibroblasts damaged by UVA irradiation was significantly increased compared with the model control group (NC) (p<0.01), with upregulation rates of 9.93% and 18.65%, respectively.

[0047] Experimental results showed that 0.1%–0.2% of sulphurine inhibited the degradation and loss of elastin in human skin fibroblasts damaged by UVA irradiation.

[0048] It will be apparent to those skilled in the art that this application is not limited to the details of the exemplary embodiments described above, and that this application can be implemented in other specific forms without departing from the spirit or essential characteristics of this application. Therefore, the embodiments should be considered illustrative and non-limiting in all respects, and the scope of this application is defined by the appended claims rather than the foregoing description. Thus, all variations falling within the meaning and scope of equivalents of the claims are intended to be included within this application. No reference numerals in the claims should be construed as limiting the scope of the claims.

Claims

1. An anti-aging composition, characterized in that, It includes royal jelly polypeptide, Dendrobium officinale stem extract solution, ginsenoside solution and copper gluconate; the mass ratio of the royal jelly polypeptide, Dendrobium officinale stem extract solution, ginsenoside solution and copper gluconate is 3-5:18-22:18-22:4-6.

2. The anti-aging composition according to claim 1, characterized in that, It also includes a synergist, which is selected from at least one of Inonotus obliquus extract and Fucus vesiculosus extract; The mass ratio of the synergist to royal jelly polypeptide, Dendrobium officinale stem extract solution, ginsenoside solution and copper gluconate is 4-6:3-5:18-22:18-22:4-6.

3. The anti-aging composition according to claim 1, characterized in that, The royal jelly polypeptide is a mixture of hydrolyzed royal jelly protein and maltodextrin, and the mass ratio of hydrolyzed royal jelly protein to maltodextrin is 1:8-10.

4. The anti-aging composition according to claim 1, characterized in that, By mass, it includes the following components: Royal jelly polypeptides, 3-5 parts; 18–22 parts of Dendrobium officinale stem extract solution; 18-22 parts of ginsenoside solution; 4-6 parts of copper gluconate; 40-50 parts water; Butanediol 4-6 parts; 0.1 to 1 part of 1,2-hexanediol; 0.1 to 1 part of p-hydroxyacetophenone.

5. Use of the anti-aging composition as described in any one of claims 1-4 to prepare skin care products.

6. A skincare product, characterized in that, Contains an anti-aging composition as described in any one of claims 1-4.

7. The skincare product according to claim 6, characterized in that, The content of anti-aging composition in skin care products is 0.05-10 wt%.

8. The skincare product according to claim 6, characterized in that, The skincare product is one of the following: lotion, cream, spray, serum, essential oil, mask, or gel.

Images